Cargando…
Epigenetic Targets in Schizophrenia Development and Therapy
Schizophrenia is regarded as a neurodevelopmental disorder with its course progressing throughout life. However, the aetiology and development of schizophrenia are still under investigation. Several data suggest that the dysfunction of epigenetic mechanisms is known to be involved in the pathomechan...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046502/ https://www.ncbi.nlm.nih.gov/pubmed/36979236 http://dx.doi.org/10.3390/brainsci13030426 |
_version_ | 1785013688739037184 |
---|---|
author | Wawrzczak-Bargieła, Agnieszka Bilecki, Wiktor Maćkowiak, Marzena |
author_facet | Wawrzczak-Bargieła, Agnieszka Bilecki, Wiktor Maćkowiak, Marzena |
author_sort | Wawrzczak-Bargieła, Agnieszka |
collection | PubMed |
description | Schizophrenia is regarded as a neurodevelopmental disorder with its course progressing throughout life. However, the aetiology and development of schizophrenia are still under investigation. Several data suggest that the dysfunction of epigenetic mechanisms is known to be involved in the pathomechanism of this mental disorder. The present article revised the epigenetic background of schizophrenia based on the data available in online databases (PubMed, Scopus). This paper focused on the role of epigenetic regulation, such as DNA methylation, histone modifications, and interference of non-coding RNAs, in schizophrenia development. The article also reviewed the available data related to epigenetic regulation that may modify the severity of the disease as a possible target for schizophrenia pharmacotherapy. Moreover, the effects of antipsychotics on epigenetic malfunction in schizophrenia are discussed based on preclinical and clinical results. The obtainable data suggest alterations of epigenetic regulation in schizophrenia. Moreover, they also showed the important role of epigenetic modifications in antipsychotic action. There is a need for more data to establish the role of epigenetic mechanisms in schizophrenia therapy. It would be of special interest to find and develop new targets for schizophrenia therapy because patients with schizophrenia could show little or no response to current pharmacotherapy and have treatment-resistant schizophrenia. |
format | Online Article Text |
id | pubmed-10046502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100465022023-03-29 Epigenetic Targets in Schizophrenia Development and Therapy Wawrzczak-Bargieła, Agnieszka Bilecki, Wiktor Maćkowiak, Marzena Brain Sci Review Schizophrenia is regarded as a neurodevelopmental disorder with its course progressing throughout life. However, the aetiology and development of schizophrenia are still under investigation. Several data suggest that the dysfunction of epigenetic mechanisms is known to be involved in the pathomechanism of this mental disorder. The present article revised the epigenetic background of schizophrenia based on the data available in online databases (PubMed, Scopus). This paper focused on the role of epigenetic regulation, such as DNA methylation, histone modifications, and interference of non-coding RNAs, in schizophrenia development. The article also reviewed the available data related to epigenetic regulation that may modify the severity of the disease as a possible target for schizophrenia pharmacotherapy. Moreover, the effects of antipsychotics on epigenetic malfunction in schizophrenia are discussed based on preclinical and clinical results. The obtainable data suggest alterations of epigenetic regulation in schizophrenia. Moreover, they also showed the important role of epigenetic modifications in antipsychotic action. There is a need for more data to establish the role of epigenetic mechanisms in schizophrenia therapy. It would be of special interest to find and develop new targets for schizophrenia therapy because patients with schizophrenia could show little or no response to current pharmacotherapy and have treatment-resistant schizophrenia. MDPI 2023-03-01 /pmc/articles/PMC10046502/ /pubmed/36979236 http://dx.doi.org/10.3390/brainsci13030426 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wawrzczak-Bargieła, Agnieszka Bilecki, Wiktor Maćkowiak, Marzena Epigenetic Targets in Schizophrenia Development and Therapy |
title | Epigenetic Targets in Schizophrenia Development and Therapy |
title_full | Epigenetic Targets in Schizophrenia Development and Therapy |
title_fullStr | Epigenetic Targets in Schizophrenia Development and Therapy |
title_full_unstemmed | Epigenetic Targets in Schizophrenia Development and Therapy |
title_short | Epigenetic Targets in Schizophrenia Development and Therapy |
title_sort | epigenetic targets in schizophrenia development and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046502/ https://www.ncbi.nlm.nih.gov/pubmed/36979236 http://dx.doi.org/10.3390/brainsci13030426 |
work_keys_str_mv | AT wawrzczakbargiełaagnieszka epigenetictargetsinschizophreniadevelopmentandtherapy AT bileckiwiktor epigenetictargetsinschizophreniadevelopmentandtherapy AT mackowiakmarzena epigenetictargetsinschizophreniadevelopmentandtherapy |